441
Views
19
CrossRef citations to date
0
Altmetric
Pharmacological Aspects

Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects

Variabilidad de la respuesta al tratamiento antipsicotico en la esquizofrenia: aspectos farmacogenéticos

Variabilité de la réponse au traitement antipsychotique dans la schizophrénie: aspects pharmacogénomiques

&

REFERENCES

  • StipE.Happy birthday neuroleptics! 50 years later: la folie du doute.Eur Psychiatry.20021711511912052571
  • BottlenderR.SatoT.JagerM.et al.The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia.Schizophr Res.200362374412765741
  • KaneJ M.HonigfeldG.SingerJ.MeltzerH.Clozapine in treatment-resistant schizophrenics.Psychopharmacol Bull.19882462673290950
  • HippiusH.A historical perspective of clozapine.J Clin Psychiatry.199960(suppl 12)222310372606
  • FlockhartDA.OesterheldJR.Cytochrome P450–mediated drug interactions.Child Adolesc Psychiatr Clin N Am.20009437610674190
  • KroemerHK.EichelbaumM.“It's the genes, stupid.” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.Life Sci.199556228522987791516
  • UsukiE.PearceR.ParkinsonA.CastagnolN Jr.Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.Chem Res Toxicol.199698008068831826
  • KalgutkarAS.TaylorTJ.VenkatakrishnanK.IsinEM.Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.Drug Metab Dispos.20033124324912584149
  • HallidayGM.PondSM.CartwrightH.McRitchieDA.CastagnoliN Jr.Van der SchyfCJ.Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol.Exp Neurol.199915815516310448427
  • SchinkelAH.WagenaarE.MolCA.van DeemterL.P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.J Clin Invest.199697251725248647944
  • BalramC.SharmaA.SivathasanC.LeeEJ.Frequency of C34357T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates.Br J Clin Pharmacol.200356788312848778
  • HoffmeyerS.BurkO.von RichterO.et al.Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.Proc Natl Acad Sci U S A.2000973473347810716719
  • KroetzDL.Pauli-MagnusC.HodgesLM.et al.Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.Pharmacogenetics.20031348149412893986
  • SeemanP.Van TolHH.Dopamine receptor pharmacology.Curr Opin Neurol Neurosurg.199366026088104554
  • McRitchieDA.CartwrightH.PondSM.et al.The midbrain dopaminergic cell groups in the baboon Papio ursinus. Brain Res Bull.19984761162310078618
  • GriffonN.CrocqMA.PilonC.et al.Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia.Am J Med Genet.19966763708678117
  • ArranzMJ.KerwinRW.Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment.Ann Med.20003212813310766404
  • ArranzMJ.MunroJ.BirkettJ.et al.Pharmacogenetic prediction of clozapine response.Lancet.20003551615161610821369